The plan is
in the scan

Pixclara® (18F-FET) is the first and only FDA-approved amino acid PET imaging agent indicated to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older1,2

Pixclara® accurately differentiated true tumor progression from treatment-related change.2

See the Data

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend 18F-FET PET imaging.3

Learn More

Telix Pharmaceuticals is committed to advancing precision medicine and expanding diagnostic options for patients with glioma

18F-FET, 18F-fluoro-ethyl-tyrosine; FDA, US Food and Drug Administration; NCCN, National Comprehensive Cancer Network; PET, positron emission tomography.